<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465801</url>
  </required_header>
  <id_info>
    <org_study_id>RG01N-0778</org_study_id>
    <nct_id>NCT02465801</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein</brief_title>
  <official_title>Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin SinoBiotech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin SinoBiotech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dosages of recombinant human serum
      albumin/granulocyte colony-stimulating factor fusion protein by injection for preventing
      neutrophilic granulocytopenia among chemotherapy patients.

      Conduct Pharmacokinetics (PK) study on recombinant human serum albumin/granulocyte
      colony-stimulating factor fusion protein with recombinant human granulocyte
      colony-stimulating factor injection as a control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Brief Protocol: Treat the patients taking Taxotere+Epirubicin+Cyclophosphamide (TEC)
           treatment or Taxotere+Epirubicin (TE) treatment chemotherapy with the study medicine or
           positive control during the period between two chemotherapy treatments.

        -  Positive control：recombinant human granulocyte colony-stimulating factor injection.

        -  Targeted patients: breast cancer

        -  Grouping: Group 1: 1.2 mg recombinant human serum albumin/granulocyte colony-stimulating
           factor fusion protein with TEC or TE treatment; Group 2: 1.5 mg recombinant human serum
           albumin/granulocyte colony-stimulating factor fusion protein with TEC or TE treatment;
           Group 3: positive control with TEC or TE treatment.

        -  Number of patients: 216

        -  Concomitant medicines will be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2014</start_date>
  <completion_date type="Actual">April 26, 2016</completion_date>
  <primary_completion_date type="Actual">December 23, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean of duration for class IV neutrophilic granulocytopenia</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean of duration for class IV neutrophilic granulocytopenia</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean of duration for ANC up to 2.0×109/L</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The usage of antibiotics</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>febrile neutropenia</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: HSA-GCSF 1.2 mg
Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o`clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:HSA-GCSF 1.5 mg
Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o`clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.
Intervention: Drug: TE or TEC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: GCSF
Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o`clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.
Intervention: Drug: TE or TEC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSA-GCSF 1.2 mg</intervention_name>
    <description>Human Serum Albumin GCSF 1.2mg at day 3 and Day 7</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSA-GCSF 1.5 mg</intervention_name>
    <description>Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCSF</intervention_name>
    <description>GCSF 5 mcg/kg/day</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65.

          -  Diagnosed breast cancer, suitable for TEC or TE .

          -  ECOG performance status 0 or 1.

          -  Adjuvant chemotherapy; new adjuvant chemotherapy; newly diagnosed class Ⅳ and prior
             chemotherapy.

          -  ANC≥1.5×10 9/L, PLT≥100×10 9/L. No bone marrow metastasis,blood coagulation function
             normally, no Hemorrhagic tendency.

          -  No obvious abnormal ecg examination.

          -  TBIL, ALT, AST≤2.5×ULN (≤5×ULN if presence of hepatic metastases).

          -  Cr, BUN≤2.5×ULN.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Chemotherapy within past 4 weeks

          -  Uncontrolled inflammatory disease,axillary temperature≥38℃.

          -  Merging other malignant tumor

          -  Pregnancy or nursing status.

          -  Participation in another clinical trial with and investigational product within 3
             months prior to study entry.

          -  Severe diabetes mellitus, or poor blood sugar controller.

          -  Allergic disease or allergic constitution. History of protein allergy.

          -  History of drug addiction and alcoholism.

          -  Hematopoietic stem cell transplantation or organ transplantation.

          -  Chronic disease of severe cardiac, kidney and liver.

          -  Other conditions that would be excluded from this study according to doctors'judgment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binhe Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Scienses</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

